Introduction
Xerostomia is the subjective complaint of oral dryness, while salivary gland hypofunction is an objective matter characterized by reduced salivary flow.[ 1 ] These two terms are often incorrectly used interchangeably.
Xerostomia is a frequent annoying condition. It is estimated that 12-47% of the elderly and 10-19.3% of people in their early 30's have been suffering from dry mouth.[ 2 3 4 ] The symptoms of xerostomia are as follows: Cracked peeled atrophic lips, glossitis, progressive cervical, or cusp tip caries even with optimum oral hygiene, candidiasis, and pale corrugated dry buccal mucosa. The size, texture and tenderness of salivary glands should be assessed. Xerostomia can lead to dysphagia, dysgeusia, oral pain, dental caries, oral infection, periodontal disease, and finally can affect the health-related quality-of-life.[ 5 6 7 8 ] Malnutrition and psychosocial problems could be associated with dry mouth as well.[ 8 ] The basis of xerostomia is the alteration in both quantitative and qualitative function of salivary glands.[ 6 ] There are multiple causes with various mechanisms of xerostomia such as systemic diseases, anticholinergic effects of many drugs, psychological conditions, alcohol, head and neck radiation therapy, and physiological changes, but xerostomia-related systemic diseases have not been addressed as much as they worth it.[ 9 ] In order to better understanding, diseases which cause xerostomia, the underlying mechanisms and the incidence or prevalence of dry mouth due to systemic conditions are summarized in Tables 1 and 2 . Multiple methods have been described to manage xerostomia. Saliva substitutes, topical stimulants, and parasympathetic agonists such as pilocarpine and cevimeline are approved medications to treat xerostomia.[ 10 ] Early detection of these diseases may aid to timely treatment of xerostomia. Some of these systemic conditions are so severe that distract the attention of health care workers away from the complications such as xerostomia, which might cause additional discomfort for the patient.
Table 1
Mechanisms of xerostomia due to systemic diseases
Table 2
Incidence or prevalence of xerostomia due to systemic diseases
The aim of this study was to describe systemic diseases leading to xerostomia to provide physicians and dentists with an update and comprehensive source for their clinical practice.
Methods of Literature Search
We used various general search engines such as Google, Google Scholar, and Yahoo as well as bibliographic databases such as PubMed, PubMed Central, Medline Plus, Medknow, EBSCO, ScienceDirect, Scopus, WebMD, EMBASE, and three authorized textbooks to find relevant topics by means of medical subject headings keywords such as “xerostomia,” “hyposalivations,” “mouth dryness,” “disease,” and “systemic.” The search was accomplished in 2013 and limited to English-language articles published over the last 40 years in both medical and dental journals. Totally, 258 articles were identified. After provisional assessment of the titles and abstracts by two reviewers, 106 articles were found to be relevant to the topic, and out of them 97 were available for us including 20 reviews and meta-analysis, 59 original papers, and 18 case reports regarding systemic disease resulting to xerostomia. Our review included articles published between 1997-2013, in the years of 1974, 1980, 1983, 1987, 1989, and 1990.
Results
After compilation of information from relevant articles and updated textbooks, we categorized systemic diseases resulting in xerostomia to endocrine diseases, viral infections, bacterial infections, autoimmune diseases, granulomatous diseases, storage diseases, and some other unclassified diseases as follows. Meanwhile, the underlying mechanisms of xerostomia due to systemic diseases, and the incidence or prevalence of xerostomia in each disease were summarized in Tables 1 and 2 .
Endocrine diseases
Diabetes mellitus
Diabetes mellitus is an endocrine disease characterized by the deficit in production of insulin with consequent alteration of metabolism and balance of glucose concentration. According to its etiology, it is classified as Type 1 and 2.[ 11 ] Type 1 diabetes mellitus is a metabolic dysfunction characterized by hyperglycemia resulting from definite shortage of insulin secretion caused by autoimmune illness and genetic factors.[ 12 ] Type 2 diabetes mellitus (formerly known as non-insulin-dependent diabetes mellitus) is the most common form of disease featured by hyperglycemia, insulin resistance, and relative insulin deficiency. Type 2 diabetes results from interaction between genetic, environmental and behavioral risk factors.[ 13 ] It is estimated that there will be 380 million persons with diabetes mellitus in 2025.[ 14 ]
Patients with uncontrolled diabetes often report dry mouth, which is believed to be due to polyuria, dehydration, and autonomic dehydration.[ 11 ] The prevalence of xerostomia was reported in 14-62% of diabetes mellitus 2 cases,[ 15 16 17 ] and it was found in 38.5% and 53% of children and adolescents subjects with diabetes mellitus 1, respectively.[ 17 18 ]
Thyroid disease
Autoimmune thyroid disease, including Graves’ disease and Hashimoto's thyroiditis, is one of the most common immune-mediated conditions.[ 19 ] Autoimmune thyroid disease is characterized by the presence of serum antibodies against thyroid-specific or thyroid-restricted antigens like the thyroid stimulating hormone receptor, thyroperoxidase, and thyroglobulin).[ 20 ] The prevalence of autoimmune thyroid disease in the general population varies among countries. Prevalence has been estimated as 5-15% in women and 1-5% in men. In other words, autoimmune thyroid disease can be regarded as the most common autoimmune endocrine disease.[ 21 ] A considerable number of patients with primary Sjögren's syndrome (pSS) along with thyroid disease diagnosed by laboratory data and clinical presentation were reported.[ 22 ] The coexistence of Sjögren's syndrome and thyroiditis is frequent suggesting a common genetic or environmental predisposing factor with similar pathogenic mechanisms. pSS was reported to be 10 times more frequent in patients with autoimmune thyroid disease, while autoimmune thyroiditis was 9 times more frequent in pSS. Therefore, Sjögren's syndrome should be studied in patients with thyroid disease and vice versa.[ 23 ]
Viral infections
Human immunodeficiency virus
Human immunodeficiency virus (HIV) infection is one of the most devastating infections in modern times. Oral manifestations of HIV infection occur in approximately 30-80% of patients.[ 24 ] Oral lesions are among the early signs of HIV infection and can predict progression to acute immunodeficiency syndrome. The more common HIV-related lesions include oral candidiasis, herpes simplex infection, oral Kaposi's sarcoma, oral hairy leukoplakia, parotid gland enlargement, periodontal diseases (linear gingival erythema and necrotizing ulcerative periodontitis), human papilloma virus-associated warts, and ulcerative conditions including herpes simplex virus lesions, recurrent aphthous ulcers, neutropenic ulcers, and xerostomia.[ 25 26 ] Xerostomia is due to the side effects of HIV medications (e.g., didanosine) or the proliferation of CD8 + cells in the major salivary glands.[ 26 ] Parotid hypertrophy as a compensative reaction has been also found more commonly in HIV-positive children.[ 27 28 ] Xerostomia has been estimated as 1.2-40% in HIV-positive patients.[ 26 29 30 31 32 33 ] Although the role of HIV on xerostomia is relatively clear, there is a controversy about xerostomia prevalence as demonstrated by Sontakke et al ., Pinheiro et al ., and Nittayananta et al .[ 32 33 34 ] There is another conflict about xerostomia-related HIV medications in the literature, for example Lin claimed that xerostomia was not compounded by medications.[ 35 ] In contrast, some researchers believe that taking anti-HIV drugs is effective on the prevalence of xerostomia.[ 26 32 ]
Hepatitis C virus
The hepatitis C virus (HCV) is a linear, single-stranded RNA virus of the Flaviviridae family that was first identified in 1989.[ 36 ] HCV infection is a major health problem among the general population, and its extrahepatic manifestations have also been reported like Sicca syndrome.[ 37 ] Several autoimmune and immune complex-mediated disorders have been proposed to be related to HCV infection such as essential mixed cryoglobulinemia, which is frequently associated with Sjögren's syndrome. The association between HCV and Sjögren's syndrome may be related to the following reasons: (1) close association between HCV infection and mixed cryoglobulinemia, (2) the salivary gland tropism of HCV.[ 38 ] However, some studies did not find any relationship between xerostomia and the presence of HCV infection.[ 39 40 ] Xerostomia has been found among 5-55% of HCV-infected patients.[ 36 38 39 41 42 ] Xerostomia is also an adverse event during ribavirin-interferon therapy.[ 43 44 ]
Epstein-Barr virus
Epstein-Barr virus (EBV) is a human herpes virus that establishes long-term latent infection in B-lymphocytes named EBV infectious mononucleosis (EBV-IM).[ 45 ] EBV-IM is a common infection that affects 25-30% of adolescents and adults up to 30 years of age.[ 46 ] Association between EBV and autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, multiple sclerosis, autoimmune thyroiditis, inflammatory bowel diseases, insulin-dependent diabetes mellitus, systemic sclerosis, myasthenia gravis, autoimmune liver diseases, and Sjögren's syndrome have been suggested.[ 47 ] It is proposed that the initiating event in pSS is an infection with EBV, and the autoimmune exocrinopathy that progresses to keratoconjunctivitis Sicca and xerostomia is sequelae to this process. It is noted that during EBV infection, there are multiple copies of the EBV-encoded small RNAs available to bind to the La ribonucleoprotein and when infection occurs in subjects who are genetically predisposed to autoimmunity and have an impaired T-cell-mediated response to EBV, there is a loss of immunological tolerance to La with production of anti-La (SS-B). Thus the inflammatory process in exocrine glands, which culminates in the Sicca syndrome is due to the combined effects of chronic EBV infection and autoimmunity. The mean titer of anti-EBV nuclear-antigen antibodies was significantly higher in Sjögren's syndrome patients than in normal people.[ 48 ]
Cytomegalovirus
Cytomegalovirus (CMV) is a common infection with a seroprevalence among adolescents ranging from 47% to 89%.[ 49 ] The persistence of CMV with alteration of cell surface expression in certain tissues may initiate the tissue destruction that leads to the clinical manifestations of Sjögren's syndrome. Ductal cells of salivary and lacrimal glands are immunologically attacked due to CMV antigenic expression. The destruction of these ducts leads to xerostomia.[ 50 ] However, no relationship between xerostomia and anti-CMV antibodies was noted.[ 51 ]
Human T-lymphotropic virus type 1
Human T-lymphotropic virus Type 1 (HTLV-1) is known to cause HTLV-associated myelopathy (HAM)/tropical spastic paraparesis and adult T-cell leukemia.[ 52 ] It is estimated that 15-20 million persons are currently infected with HTLV-1 worldwide.[ 53 ]
Retroviruses such as HTLV-1 and HIV infect immunocompetent cells, resulting in the destruction or overstimulation of T-cells, and act as potential triggers for autoimmune disease.[ 54 ]
Previous studies reported a high prevalence rate of anti-HTLV-1 antibodies in the peripheral blood in 3.8-36.7% of patients with Sjögren's Syndrome.[ 55 56 57 58 ]
Bacterial infections
Actinomycosis
Actinomycosis is an anaerobic bacterial infection affecting men more frequently between the ages of 30-60 years. Almost half of actinomycosis cases occur in the cervicofacial region, and salivary glands may be involved as well. The organism can colonize inside the ducts of both submandibular and parotid glands and leads to abscess formation in the submandibular and masseter spaces, respectively.[ 59 60 61 ]
Autoimmune diseases
Rheumatoid arthritis
Rheumatoid arthritis is a systemic disease of connective tissue origin, which affects 1% of the world population. Women have a 3-fold higher incidence than do men. RA frequently presents with extra-articular features such as hematologic, neurologic, and cardiovascular involvement concomitant with dysfunction of lacrimal and salivary glands. Zalewska et al . showed impairment of salivary immunity system of the oral cavity in xerostomic patients with RA.[ 62 ] Secondary Sjögren's syndrome is associated with xerostomia and occurs with autoimmune diseases most frequently with RA.[ 63 ]
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an inflammatory connective tissue disease with characteristic autoantibodies. SLE is much more common in women than men. It may occur at any age, but appears most often in people between the ages of 10 and 50. More than 75% of patients with SLE are affected with xerostomia. Coexistence of Sjögren's syndrome and SLE has been found in 1/3 of SLE patients. SLE has been shown to be associated with a decreased unstimulated salivary flow rate.[ 64 ]
Primary biliary cirrhosis
Primary biliary cirrhosis (PBC) is a cholestatic autoimmune disease predominantly of middle-aged women with progressive destruction of interlobular bile ducts.[ 65 ] The most autoimmune disease in PBC patients is Sjögren's syndrome[ 66 ] whose symptoms have been observed in 47-73% of patients[ 67 68 ] Xerostomia as well as dysphagia seems to be associated with PBC.[ 69 ]
Scleroderma
Progressive systemic sclerosis or scleroderma is a chronic sclerotic disease with deposition of extracellular matrix throughout connective tissue and vascular abnormalities, which leads to tissue hypoxia.[ 70 ] Fibrosis of capillaries, excretory ducts and acini of salivary and lacrimal glands are associated with xerostomia as oral manifestations of scleroderma.[ 71 ] Lymphocytic infiltration has been observed among 15% of patients with systemic sclerosis, which is a sign of secondary Sjögren's syndrome.[ 72 ]
Granulomatous diseases
Sarcoidosis
Sarcoidosis is a systemic inflammatory disease with unknown etiology characterized by the presence of noncaseating granulomas that can affect any organ (mostly lungs and lymph nodes).[ 73 ] Coexistence of parotid and submandibular gland swelling and xerostomia has been reported in sarcoidosis patients.[ 74 75 76 ] Mansour et al ., identified five patients representing both clinical and histological features of Sjögren's syndrome and sarcoidosis, suggesting inclusion of sarcoidosis as diagnostic criteria for Sjögren's syndrome.[ 74 ]
The salivary glands could be affected by sarcoidosis as well, which was reported in 6% of the cases. Parotid salivary gland enlargement was also detected in 6% of the patients.[ 74 ] Parotid gland enlargement in patients presenting with Sicca symptoms is believed to be of clinical significance. Such finding might be more likely associated with sarcoidosis, especially in patients presenting with negative serologic profiles.[ 74 ]
Tuberculosis
Tuberculosis (TB) is a chronic bacterial infection, caused by Mycobacterium TB leading to formation of granulomas in infected tissues. The lungs are most commonly affected, but other tissues, including the salivary glands, may be involved. Patients with TB may experience xerostomia and/or salivary gland swelling, with granuloma or cyst formation within the affected glands. Salivary gland enlargement usually presents as part of a characteristic symptom complex, however salivary gland changes have been reported in the absence of systemic symptoms.[ 77 ]
Granulomatous diseases such as sarcoidosis and TB may cause salivary gland hypofunction and lead to xerostomia.[ 78 ]
Storage diseases
Hemochromatosis
Hemochromatosis is defined as a pathological condition with iron overload in vital organs with a hereditary/primary cause.[ 79 ] Organs commonly affected by hemochromatosis are liver, heart, and endocrine glands. Iron deposition in salivary glands causes hyposalivation. Patients with normal ferritin level had normal salivary flow rate, whereas those with high levels of ferritin showed decreased stimulatory salivary flow rate.[ 79 80 ]
Amyloidosis
Amyloidosis is characterized by deposition of an extracellular protein-like material called amyloid. Amyloidosis causes various effects on different organs with a variety of extensions. In addition, amyloidosis may be associated with multiple myeloma or chronic infections. Amyloidosis may be accompanied with oral involvement in the form of macroglossia (10-40%), oral amyloid nodules, and dry mouth due to amyloid infiltration and destruction of salivary glands.[ 81 ] A case of pSS manifested as localized cutaneous nodular amyloidosis has been reported.[ 82 ] Meanwhile, a relationship between amyloidosis and xerostomia has been documented.[ 82 83 84 ]
Others
End-stage renal disease
End-stage renal disease (ESRD) represents a clinical state or condition with irreversible loss of the endogenous renal function to a degree, which is sufficient to render the patient permanently dependent upon renal replacement therapy in the form of dialysis or kidney transplantation. ESRD leads to accumulation of certain toxic elements, which affects normal functions of the body, and may have significant complications including cardiovascular disease, immune deficiency, anemia, renal function impairment, and bone disease.[ 85 ] Xerostomia was found in 28-59% of ESRD patients due to inability of kidneys to reabsorb sodium and the resultant polyuria.[ 86 87 ]
Ectodermal dysplasia
Ectodermal dysplasia is a hereditary disease causing anomalies in tissues of ectodermal origin. The significance of this disease lies in severe hypodontia, and an accompanying hypoplasia of the alveolar process. The clinical condition is aggravated by a significant xerostomia as a result of salivary gland aplasia or hypoplasia.[ 88 89 ] However, in some patients with ectodermal dysplasia with the presence of salivary glands, hyposalivation have been reported. In a study of 39 patients with ectodermal dysplasia, salivary flow rate was decreased in 13 (33.3%) patients.[ 90 ]
Hematopoietic stem cell transplantation and chronic graft-versus-host disease
Chronic graft-versus-host disease (cGVHD) is a multi-organ involvement that occurs post hematopoietic stem cell transplantation (HSCT), with the mouth being one of the most frequently affected sites.[ 91 ] The pathogenesis of GVHD is based on donor graft T-lymphocytes that recognize antigenic disparities between donor and recipient and the dysregulation of a broad panel of cytokines. GVHD occurs in 40-70% of patients treated by bone marrow and peripheral blood stem cell transplantation.[ 92 ] Oral manifestations are common in patients diagnosed with chronic graft-versus-host-disease.[ 91 ] Hull et al . mentioned xerostomia as the most common oral symptom in patients with history of HSCT with the majority of patients (53%) having clinical markers of oral cGVHD.[ 93 ] Noce et al . reported that 59.1% of patients diagnosed with cGVHD had salivary gland dysfunction.[ 91 ] Boer et al . showed a decrease in salivary flow rate (16% of patients) and a relation between hyposalivation intensity and elapsed time after HSCT.[ 94 ] There is similarity in oral clinical manifestations of GVHD and Sjögren's Syndrome because of the same autoimmune nature, but differences have also been found.[ 95 ] The suggested pathophysiological mechanisms of xerostomia and hyposalivation observed in GVHD are lymphocytic infiltration, parenchymal destruction, and fibrosis within salivary gland tissue.[ 95 ]
Parkinson's disease
Parkinson's disease (PD) is a relatively common, progressive, debilitating, and neurological disorder. Cardinal symptoms are resting tremor, bradykinesia, akinesia, restricted mobility, and postural instability. Levodopa (L-DOPA) has been used as a primary drug for over 30 years. L-DOPA is converted into dopamine in the dopaminergic neurons by DOPA decarboxylase enzyme. Proulx et al . have reported that patients with PD produce less saliva than normal. Factors influencing the production of saliva include the use of levodopa and female gender.[ 96 ] Hyposialorrhea is an early autonomic manifestation of PD.[ 97 ]
Conclusion
Salivary glands are involved due to many systemic diseases with the resultant complication of xerostomia. Autoimmune diseases, diabetes mellitus, ESRD, and GVHD are frequently associated with salivary hypofunction. The underlying mechanism of xerostomia differs in terms of disease. Autoimmunity accounts for xerostomia related to SLE, RA, PBC, thyroid disease, and some viral infections. Some conditions affect salivary glands through infiltration of immunocompetent cells or granuloma formation such as HIV infection, GVHD, sarcoidosis, and TB. Polyuria and dehydration is responsible for dry mouth associated with diabetes and end-stage renal failure, while GVHD and scleroderma cause xerostomia because of fibrosis. Deposition of proteinaceous substances and bacterial infection are also mentioned as alternative mechanisms for xerostomia. Identification of the main reason of xerostomia helps attain timely diagnosis and more appropriate treatment plan.
Source of Support: Nil.
Conflict of Interest: None declared.
1 Thomson WM Chalmers JM Spencer AJ Williams SM The Xerostomia Inventory: A multi-item approach to measuring dry mouth Community dent health 1999 16 12 7 10697349
2 Thomson WM Issues in the epidemiological investigation of dry mouth Gerodontology 2005 22 65 76 15934347 10.1111/j.1741-2358.2005.00058.x
3 Murray Thomson W Poulton R Mark Broadbent J Al-Kubaisy S Xerostomia and medications among 32-year-olds Acta Odontol Scand 2006 64 249 54 16829502 10.1080/00016350600633243 PMC2249168
4 Guggenheimer J Moore PA Xerostomia etiology, recognition and treatment JADA 2003 134 61 9 12555958 10.14219/jada.archive.2003.0018
5 Fox PC Xerostomia: Recognition and management Dent Assist 2008 77 44 8 18982854
6 Grötz K Genitsariotis S Vehling D Al-Nawas B Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy Support Care Cancer 2003 11 717 21 12910407 10.1007/s00520-003-0506-0
7 Momm F Volegova-Neher NJ Schulte-Mönting J Guttenberger R Different saliva substitutes for treatment of xerostomia following radiotherapy Strahlenther Onkol 2005 181 231 6 15827692 10.1007/s00066-005-1333-7
8 Turner M Jahangiri L Ship JA Hyposalivation, xerostomia and the complete denture. A systematic review JADA 2008 139 146 50 18245681 10.14219/jada.archive.2008.0129
9 Daniels TE Evaluation, differential diagnosis, and treatment of xerostomia J Rheumatol Suppl 2000 61 6 11128701
10 Rayman S Dincer E Almas K Xerostomia: Diagnosis and management in dental practice N Y State Dent J 2010 76 24 7 20441043
11 Vasconcelos ACU Soares MSM Almeida PC Soares TC Comparative study of the concentration of salivary and blood glucose in type 2 diabetic patients J Oral Sci 2010 52 293 8 20587956 10.2334/josnusd.52.293
12 Bakianian Vaziri P Vahedi M Mortazavi H Abdollahzadeh Sh Hajilooi M Evaluation of salivary glucose, IgA and flow rate in diabetic patients: A case-control study J Dent (Tehran) 2010 7 13 8 21998770 PMC3184719
13 Olokoba AB Obateru OA Olokoba LB Type 2 diabetes mellitus: a review of current trends Oman Med J 2012 27 269 23071876 10.5001/omj.2012.68 PMC3464757
14 Casqueiro J Casqueiro J Alves C Infections in patients with diabetes mellitus: A review of pathogenesis Indian J Endocrinol Metab 2012 16 S27 22701840 10.4103/2230-8210.94253 PMC3354930
15 Bajaj S Prasad S Gupta A Singh VB Oral manifestations in type-2 diabetes and related complications Indian J Endocrinol Metab 2012 16 777 9 23087863 10.4103/2230-8210.100673 PMC3475903
16 Khovidhunkit S-oP Suwantuntula T Thaweboon S Mitrirattanakul S Chomkhakhai U Khovidhunkit W Xerostomia, hyposalivation, and oral microbiota in type 2 diabetic patients: A preliminary study J Med Assoc Thai 2009 92 1220 8 19772183
17 Busato IMS Ignácio SA Brancher JA Grégio AMT Machado MÂN Azevedo-Alanis LR Impact of xerostomia on the quality of life of adolescents with type 1 diabetes mellitus Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 108 376 82 19716505 10.1016/j.tripleo.2009.05.005
18 Costa CC Resende GB Souza JM Tavares SS Almeida IC Study of the oral manifestations in diabetic children and their correlation variables Arq Bras Endocrinol Metabol 2004 48 374 8 15640899 10.1590/s0004-27302004000300007
19 Cooper JD Simmonds MJ Walker NM Burren O Brand OJ Guo H Seven newly identified loci for autoimmune thyroid disease Hum Mol Genet 2012 21 5202 8 22922229 10.1093/hmg/dds357 PMC3490518
20 Hutfless S Matos P Talor MV Caturegli P Rose NR Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease J Clin Endocrinol Metab 2011 96 E1466 71 21715532 10.1210/jc.2011-0228 PMC3167665
21 Cárdenas Roldán J Amaya-Amaya J Castellanos-de la Hoz J Giraldo-Villamil J Montoya-Ortiz G Cruz-Tapias P Autoimmune thyroid disease in rheumatoid arthritis: A global perspective Arthritis 2012 2012 864907 10.1155/2012/864907 PMC3505628 23209899
22 Karsh J Pavlidis N Weintraub BD Moutsopoulos HM Thyroid disease in Sjögren's syndrome Arthritis Rheum 1980 23 1326 9 7447970 10.1002/art.1780231118
23 D’Arbonneau F1 Ansart S Le Berre R Dueymes M Youinou P Pennec YL Thyroid dysfunction in primary Sjögren's syndrome: A long-term followup study Arthritis Rheum 2003 49 804 9 14673967 10.1002/art.11460
24 Okoje V Obiechina A Aken’Ova Y Orofacial lesions in 126 newly diagnosed HIV/AIDS patients seen at the University College Hospital, Ibadan Afr J Med Med Sci 2006 35 97 101 17209335
25 Nokta M Oral manifestations associated with HIV infection Curr HIV/AIDS Rep 2008 5 5 12 18417029 10.1007/s11904-008-0002-8
26 Reznik D Oral manifestations of HIV disease Top HIV Med 2005 13 143 8 16377852
27 Expósito-Delgado A Vallejo-Bolaños E Martos-Cobo E Oral manifestations of HIV infection in infants: A review article Med Oral Patol Oral Cir Bucal 2004 9 415 15580118
28 Pinto A De Rossi SS Salivary gland disease in pediatric HIV patients: an update J Dent Child (Chic) 2004 71 33 7 15272653
29 Sharma G Pai K Suhas S Ramapuram J Doshi D Anup N Oral manifestations in HIV/AIDS infected patients from India Oral Dis 2006 12 537 42 17054765 10.1111/j.1601-0825.2006.01232.x
30 Taiwo O Okeke E Jalo P Danfillo I Oral manifestation of HIV/AIDS in Plateau state indigenes, Nigeria West Afr J Med 2006 25 32 7 16722356 10.4314/wajm.v25i1.28242
31 Freed JR Marcus M Freed BA Der-Martirosian C Maida CA YOUNAI FS Oral health findings for HIV-infected adult medical patients from the HIV Cost and Services Utilization Study JADA 2005 136 1396 405 16255464 10.14219/jada.archive.2005.0053
32 Sontakke SA Umarji H Karjodkar F Comparison of oral manifestations with CD4 count in HIV-infected patients Indian J Dent Res 2011 22 732 22406727 10.4103/0970-9290.93470
33 Pinheiro A Marcenes W Zakrzewska J Robinson P Dental and oral lesions in HIV infected patients: a study in Brazil Int Dent J 2004 54 131 7 15218892 10.1111/j.1875-595x.2004.tb00268.x
34 Nittayananta W Chanowanna N Jealae S Nauntofte B Stoltze K Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era J Oral Pathol Med 2010 39 28 34 19709350 10.1111/j.1600-0714.2009.00826.x
35 Lin A Johnson D Stephan K Yeh C-K Alteration in salivary function in early HIV infection J Dent Res 2003 82 719 24 12939357 10.1177/154405910308200912
36 Ramos-Casals M Trejo O García-Carrasco M Font J Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection Rheumatology (Oxford) 2003 42 818 28 12730523 10.1093/rheumatology/keg299
37 Prunoiu C Georgescu EF Georgescu M Simionescu C Sjogren's syndrome associated with chronic hepatitis C-the benefit of the antiviral treatment Rom J Morphol Embryol 2008 49 557 62 19050807
38 Grossmann SdMC Teixeira R de Oliveira GC Gleber-Netto FO Araújo FMG Araújo FM Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands J Clin Pathol 2010 63 1002 7 20924089 10.1136/jcp.2010.080036
39 de Mattos Camargo Grossmann S Teixeira R de Oliveira GC do Carmo MAV Detection of HCV RNA in saliva does not correlate with salivary flow or xerostomia in patients with chronic hepatitis C Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010 109 851 6 20451844 10.1016/j.tripleo.2010.02.012
40 Carrozzo M Gandolfo S Oral diseases possibly associated with hepatitis C virus Crit Rev Oral Biol Med 2003 14 115 27 12764074 10.1177/154411130301400205
41 Nawito Z Amin A El-Fadl SA El Einen KA Sicca complex among Egyptian patients with chronic hepatitis C virus infection Clin Rheumatol 2011 30 1299 304 21487733 10.1007/s10067-011-1746-x
42 Giordano N Amendola A Papakostas P Cipolli F Agate VM Battisti E Immune and autoimmune disorders in HCV chronic liver disease: Personal experience and commentary on literature New Microbiol 2005 28 311 7 16386015
43 Nagao Y Hashimoto K Sata M Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases BMC Gastroenterol 2012 12 155 23122361 10.1186/1471-230X-12-155 PMC3503792
44 Aghemo A Rumi MG Monico S Banderali M Russo A Ottaviani F Ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis C patients Hepat Mon 2011 11 918 24 22308157 10.5812/kowsar.1735143X.733 PMC3269061
45 Arvey A Tempera I Lieberman PM Interpreting the Epstein-Barr Virus [EBV] Epigenome Using High-Throughput Data Viruses 2013 5 1042 54 23549386 10.3390/v5041042 PMC3705264
46 Hallee TJ Evans AS Niederman JC Brooks CM Voegtly JH Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years Yale J Biol Med 1974 47 182 95 4374836 PMC2595096
47 Lossius A Johansen JN Torkildsen Ø Vartdal F Holmøy T Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation Viruses 2012 4 3701 30 23342374 10.3390/v4123701 PMC3528287
48 Fox R Chilton T Scott S Benton L Howell F Vaughan J Potential role of Epstein-Barr virus in Sjögren's syndrome Rheum Dis Clin North Am 1987 13 275 92 2827246
49 Stadler LP Bernstein DI Callahan ST Ferreira J Simone GAG Edwards KM Seroprevalence of cytomegalovirus [CMV] and risk factors for infection in adolescent males Clin Infect Dis 2010 51 e76 81 20936976 10.1086/656918 PMC3699193
50 Burns J Persistent Cytomegalovirus infection-The etiology of Sjogren's Syndrome Med Hypotheses 1983 10 451 60 6308404 10.1016/0306-9877(83)90011-7
51 Scully C Sjögren's syndrome: no demonstrable association by serology of secondary Sjögren's syndrome with cytomegalovirus J Oral Pathol Med 1990 19 43 4 2156070 10.1111/j.1600-0714.1990.tb00780.x
52 Poetker SK Porto AF Giozza SP Muniz AL Caskey MF Carvalho EM Clinical manifestations in individuals with recent diagnosis of HTLV type I infection J Clin Virol 2011 51 54 8 21388871 10.1016/j.jcv.2011.02.004 PMC3074002
53 Proietti FA Carneiro-Proietti ABF Catalan-Soares BC Murphy EL Global epidemiology of HTLV-I infection and associated diseases Oncogene 2005 24 6058 68 16155612 10.1038/sj.onc.1208968
54 Manns MP Rambusch EG Autoimmunity and extrahepatic manifestations in hepatitis C virus infection J Hepatol 1999 31 Suppl 1 39 42 10622558 10.1016/s0168-8278(99)80372-9
55 Obermayer-Straub P Manns MP Hepatitis C and D, retroviruses and autoimmune manifestations J Autoimmun 2001 16 275 85 11334493 10.1006/jaut.2000.0488
56 Lee SJ Lee JS Shin MG Tanaka Y Park DJ Kim TJ Detection of HTLV-1 in the labial salivary glands of patients with Sjogren's syndrome: A distinct clinical subgroup? J Rheumatol 2012 39 809 15 22382336 10.3899/jrheum.111075
57 Hida A Kawabe Y Kawakami A Migita K Tominaga M Nakamura H HTLV-I associated Sjögren's syndrome is aetiologically distinct from anti-centromere antibodies positive Sjögren's syndrome Ann Rheum Dis 1999 58 320 2 10225819 10.1136/ard.58.5.320 PMC1752886
58 Ohyama Y Nakamura S Hara H Shinohara M Sasaki M Ikebe-Hiroki A Accumulation of human T lymphotropic virus type I-infected T cells in the salivary glands of patients with human T lymphotropic virus type I-associated Sjogren's syndrome Arthritis Rheum 1998 41 1972 8 10.1002/1529-0131(199811)41:11<1972::AID-ART12>3.0.CO;2-M 9811052
59 Neville BW Damm DD Allen CM Bouqout JE Oral and maxillofacial pathology 2009 St Louis Saunders Elsevier 203
60 Mamais C Dias A Walker J Vydianath SR Parotid actinomycosis mimicking metastatic lymphadenopathy West Indian Med J 2011 60 349 50 22224352
61 Sittitrai P Srivanitchapoom C Pattarasakulchai T Lekawanavijit S Actinomycosis presenting as a parotid tumor Auris Nasus Laryn× 2012 39 241 3 10.1016/j.anl.2011.03.011 21570224
62 Zalewska A Knaś M Waszkiewicz N Waszkiel D Sierakowski S Zwierz K Rheumatoid arthritis patients with xerostomia have reduced production of key salivary constituents Oral Surg Oral Med Oral Pathol Oral Radiol 2013 115 483 90 23312539 10.1016/j.oooo.2012.10.013
63 Anurag Gupta B Epstein JB Sroussi H Hyposalivation in elderly patients J Can Dent Assoc 2006 72 841 6 17109806
64 Jensen J Bergem H Gilboe IM Husby G Axell T Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus J Oral Pathol Med 1999 28 317 22 10432198 10.1111/j.1600-0714.1999.tb02047.x
65 Anurag Gupta B Epstein JB Sroussi H Hyposalivation in elderly patients J Can Dent Assoc 2006 72 841 6 17109806
66 Karp JK Akpek EK Anders RA Autoimmune hepatitis in patients with primary Sjögren's syndrome: A series of two-hundred and two patients Int J Clin Exp Pathol 2010 25 3 582 6 20661405 PMC2907119
67 Kumagi T Heathcote EJ Primary biliary cirrhosis Orphanet J Rare Dis 2008 23 3 1 18215315 10.1186/1750-1172-3-1 PMC2266722
68 Selmi C Meroni PL Gershwin ME Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis J Autoimmun 2012 39 34 42 22178199 10.1016/j.jaut.2011.11.005 PMC3568660
69 Mang F-W Michieletti P O’Rourke K Cauch-Dudek K Diamant N Bookman A Primary biliary cirrhosis, sicca complex, and dysphagia Dysphagia 1997 12 167 70 9190103 10.1007/PL00009532
70 Cazal C Sobral APV Neves R Freire-Filho F Cardoso A da Silveira M Oral complaints in progressive systemic sclerosis: Two cases report Med Oral Patol Oral Cir Bucal 2008 13 E114 8 18223527
71 Albilia JB Lam DK Blanas N Clokie CM Sándor GK Small mouths… Big problems? A review of scleroderma and its oral health implications J Can Dent Assoc 2007 73 831 6 18028759
72 Janin A Gosselin B Gosset D Hatron P Sauvezie B Histological criteria of Sjögren's syndrome in scleroderma Clin Exp Rheumatol 1989 7 167 2736830
73 Sekhri V Sanal S DeLorenzo LJ Aronow WS Maguire GP Cardiac sarcoidosis: A comprehensive review Arch Med Sci 2011 7 546 54 22291785 10.5114/aoms.2011.24118 PMC3258766
74 Mansour M Al-Hashimi I Wright J Coexistence of Sjögren's syndrome and sarcoidosis: A report of five cases J Oral Pathol Med 2007 36 337 41 17559494 10.1111/j.1600-0714.2007.00530.x
75 Surattanont F Mandel L Wolinsky B Bilateral parotid swelling caused by sarcoidosis JADA 2002 133 738 41 12083650 10.14219/jada.archive.2002.0270
76 Poate T Sharma R Moutasim KA Escudier M Warnakulasuriya S Orofacial presentations of sarcoidosis: A case series and review of the literature Br Dent J 2008 205 437 42 18953304 10.1038/sj.bdj.2008.892
77 Babazade F Mortazavi H Jalalian H Parotid tuberculosis: A forgotten suspicion (a case report and literature review) Int J Dermatol 2012 51 588 91 22515584 10.1111/j.1365-4632.2011.05014.x
78 Greenberg MS Glick M Ship JA Burket's Oral Medicine 2008 Ontario BC Decker Inc 213 14
79 Klopfleisch R Olias P The Pathology of comparative animal models of human haemochromatosis J Comp Pathol 2012 147 460 78 23079103 10.1016/j.jcpa.2012.09.001
80 Sánchez-Pablo M-A González-García V del Castillo-Rueda A Study of total stimulated saliva flow and hyperpigmentation in the oral mucosa of patients diagnosed with hereditary hemochromatosis. Series of 25 cases Med Oral Patol Oral Cir Bucal 2012 1 17 e45 9 22157666 10.4317/medoral.17206 PMC3448189
81 Wey SJ Chen YM Lai PJ Chen DY Primary sjögren syndrome manifested as localized cutaneous nodular amyloidosis J Clin Rheumatol 2011 17 368 70 21946462 10.1097/RHU.0b013e31823209ba
82 Elfatoiki FZ Funck Brentano E Blanc F Clerici T Saiag P Nodular cutaneous amyloidosis associated with Sjögren's syndrome Ann Dermatol Venereol 2013 140 378 81 23663711 10.1016/j.annder.2013.02.014
83 Juusela P Tanskanen M Nieminen A Kari K Suominen L Uitto VJ Kiuru-Enari S Xerostomia in hereditary gelsolin amyloidosis Amyloid 2013 20 39 44 23356404 10.3109/13506129.2013.764284
84 Sowa T Komatsu T Fujinaga T Kato T A case of solitary pulmonary nodular amyloidosis with Sjögren's syndrome Ann Thorac Cardiovasc Surg 2013 19 247 9 22971705 10.5761/atcs.cr.12.01890
85 M SP Rajan PM Santhi S Jothimalar Blood Lead in End-Stage Renal Disease Patients who were on Maintainence Haemodialysis J Clin Diagn Res 2012 6 1633 5 23373016 10.7860/JCDR/2012/4865.2627 PMC3552192
86 Postorino M Catalano C Martorano C Cutrupi S Marino C Cozzupoli P Salivary and lacrimal secretion is reduced in patients with ESRD Am J Kidney Dis 2003 42 722 8 14520622 10.1016/s0272-6386(03)00908-9
87 Dirschnabel AJ Martins AS Dantas S Ribas MO Grégio A Alanis L Clinical oral findings in dialysis and kidney-transplant patients Quintessence Int 2011 42 127 33 21359247
88 Lexner MO Bardow A Hertz JM Almer L Nauntofte B Kreiborg S Whole saliva in X-linked hypohidrotic ectodermal dysplasia Int J Paediatr Dent 2007 17 155 62 17397458 10.1111/j.1365-263X.2006.00812.x
89 Präger TM Finke C Miethke R-R Dental findings in patients with ectodermal dysplasia J Orofac Orthop 2006 67 347 55 16953354 10.1007/s00056-006-0619-4
90 Nordgarden H Jensen J Storhaug K Oligodontia is associated with extra-oral ectodermal symptoms and low whole salivary flow rates Oral Dis 2001 7 226 32 11575873
91 Noce C Gomes A Copello A Barbosa R Sant’anna S Moreira M Oral involvement of chronic graft-versus-host disease in hematopoietic stem cell transplant recipients Gen Dent 2011 59 458 62 quiz 463-4 22313917
92 Nagler RM Nagler A Salivary gland involvement in graft-versus-host disease: The underlying mechanism and implicated treatment Isr Med Assoc J 2004 6 167 72 15055275
93 Hull K Kerridge I Schifter M Long-term oral complications of allogeneic haematopoietic SCT Bone Marrow Transplant 2012 47 265 70 21441960 10.1038/bmt.2011.63
94 Boer C Correa M Miranda E de Souza C Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT Bone Marrow Transplant 2010 45 705 11 19767788 10.1038/bmt.2009.237
95 de la Rosa-Garcia E Bologna-Molina R Vega-González M de Jesus T Graft-versus-host disease, an eight case report and literature review Med Oral Patol Oral Cir Bucal 2006 11 E486 92 17072252
96 Proulx M De Courval FP Wiseman MA Panisset M Salivary production in Parkinson's disease Mov Disord 2005 20 204 7 15389996 10.1002/mds.20189
97 Cersósimo M Tumilasci O Raina G Benarroch E Cardoso E Micheli F Hyposialorrhea as an early manifestation of Parkinson disease Auton Neurosci 2009 150 150 1 19419908 10.1016/j.autneu.2009.04.004